REN001
Phase 2/3Terminated 1 views this week 0 watching💤 Quiet
Interest: 20/100
20
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Mitochondrial Myopathy
Conditions
Primary Mitochondrial Myopathy
Trial Timeline
Feb 1, 2022 → Jan 31, 2024
NCT ID
NCT05267574About REN001
REN001 is a phase 2/3 stage product being developed by OnKure Therapeutics for Primary Mitochondrial Myopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT05267574. Target conditions include Primary Mitochondrial Myopathy.
What happened to similar drugs?
20 of 20 similar drugs in Primary Mitochondrial Myopathy were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
15
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05267574 | Phase 2/3 | Terminated |
| NCT04226274 | Phase 1 | Completed |
| NCT03862846 | Phase 1 | Terminated |
Competing Products
20 competing products in Primary Mitochondrial Myopathy